Diana Graus Porta

In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

Carlos Garcı́a-Echeverrı́a, Mark Pearson, Andreas Marti et al. · Cancer Cell · 2004 · 535 citations · Full text

Cancer Research, Medicine, Receptor Tyrosine Kinase +9

Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Lipika Goyal, Supriya K. Saha, Leah Y. Liu et al. · Cancer Discovery · 2016 · 527 citations · Full text

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 484 citations · Full text

Pharmaceutical Chemistry, Tumor Biology, Medicinal Chemistry +19

Conditional disruption of β1 integrin in Schwann cells impedes interactions with axons

M. Laura Feltri, Diana Graus Porta, Stefano C. Previtali et al. · The Journal of Cell Biology · 2002 · 325 citations · Full text

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Fabrice André, Thomas Bachelot, Mario Campone et al. · Clinical Cancer Research · 2013 · 304 citations